alleviating cancer drug toxicity inhibiting bacterial enzyme 
dose-limiting side effect common colon cancer chemotherapeutic cpt severe diarrhea caused symbiotic bacterial beta-glucuronidases reactivate drug gut sought target enzymes without killing commensal bacteria essential human health potent bacterial beta-glucuronidase inhibitors identified high-throughput screening shown effect orthologous mammalian enzyme crystal structures established selectivity based loop unique bacterial beta-glucuronidases inhibitors highly effective enzyme target living aerobic anaerobic bacteria kill bacteria harm mammalian cells finally oral administration inhibitor protected mice cpt--induced toxicity thus drugs may designed inhibit undesirable enzyme activities essential microbial symbiotes enhance chemotherapeutic efficacy 
